New York Eye and Ear Infirmary

Nanoscope Therapeutics Strengthens Clinical and Regulatory Expertise With Appointment of Samuel Barone, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, September 21, 2023
University of California, San Diego Performance-Based Skills Assessment, New York Eye and Ear Infirmary, Adverum Biotechnologies, University, Therapy, Senior, Gene, Food and Drug Administration, Drug, Retina, AAV, Nanoscopic scale, Australia New Zealand Therapeutic Products Authority, Dermatology, Patient, Ophthalmology, Gemini, Air force, Entrepreneurship, Paratriathlon, Rare, FDA, Food, United States Department of the Air Force, Pharmaceutical industry, Medical device, DALLAS, Atomic de Broglie microscope

The regulatory expertise garnered during his tenure at the FDA will be instrumental as we continue to advance our pipeline through late-stage clinical development and navigate the regulatory process," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope.

Key Points: 
  • The regulatory expertise garnered during his tenure at the FDA will be instrumental as we continue to advance our pipeline through late-stage clinical development and navigate the regulatory process," said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope.
  • "Dr. Barone will support our mission to bring sight-restoring therapies to patients with inherited retinal diseases in an expeditious manner."
  • Prior to that he was Chief Medical Officer for Veloce BioPharma, a topical therapeutics company focusing on unmet clinical needs in dermatology, ophthalmology and supportive oncology.
  • He was also Chief Medical Officer for Avalanche Biotechnologies and then Senior Vice President, Clinical Development, for Adverum Biotechnologies.

New York's Premier Retina Practice Welcomes Top Retina Specialist

Retrieved on: 
Thursday, June 15, 2023
Retina, National Register of Historic Places, Macular degeneration, Education, Diabetes, Harvard University, AMD, Supplement, Columbia University Vagelos College of Physicians and Surgeons, Consultant, National Register of Historic Places listings in Weber County, Utah, Premature, VRC, AIDS, MD, Patient, National Eye Institute, Executive Committee, Fellow, Surgeon, McGill University, Diabetic retinopathy, Columbia University College of Dental Medicine, New York Eye and Ear Infirmary, S-1 Executive Committee, Retinal scan, Nursing, Physician, Ophthalmology, Shirley, Retinopathy

LONG ISLAND, N.Y, June 15, 2023 /PRNewswire-PRWeb/ -- Vitreoretinal Consultants of NY (VRC) has just announced that Dr. Pamela Ann Weber of Island Retina, an award-winning retina specialist and surgeon, has joined their retina practice. Dr. Weber is a member of the National Register's Who's Who, a Castle Connolly Top Doctor and a Newsday Top Doctor. As a physician in-step with VRC's mission to provide the highest-quality retinal care to patients, Dr. Weber expressed her enthusiasm in joining the team. "It's a privilege to help patients who need specialized, sight-saving services," said Dr. Weber. "Vitreoretinal Consultants of NY is well-known in the retinal community for their patient-centered approach to fighting retinal diseases, and I look forward to working alongside a team of nationally-recognized providers."

Key Points: 
  • Island Retina's Pamela Ann Weber, MD has joined Vitreoretinal Consultants of NY
    LONG ISLAND, N.Y, June 15, 2023 /PRNewswire-PRWeb/ -- Vitreoretinal Consultants of NY (VRC) has just announced that Dr. Pamela Ann Weber of Island Retina, an award-winning retina specialist and surgeon, has joined their retina practice.
  • Dr. Weber is a member of the National Register's Who's Who, a Castle Connolly Top Doctor and a Newsday Top Doctor.
  • As a physician in-step with VRC's mission to provide the highest-quality retinal care to patients, Dr. Weber expressed her enthusiasm in joining the team.
  • Michael Wiley, CEO at VRC, said: "We're thrilled to have Dr. Weber join our practice.

New York Times Magazine Has Named Dr. Mark Stein As A 2023 Super Doctor!

Retrieved on: 
Monday, May 22, 2023
Surgeon, University, Dental implant, Columbia University Irving Medical Center, Robert Wood Johnson Medical School, University college, Mount Sinai Beth Israel, Assistant, New York Eye and Ear Infirmary, Super, The New York Times Magazine, Publication, MD, Patient, Physician, New York University College of Dentistry, Staten Island University Hospital, Oral, Dentistry, University of Medicine and Dentistry of New Jersey, Filler (linguistics), Nursing, Oral and maxillofacial surgery, New York University, DDS

New York City, May 22, 2023 (GLOBE NEWSWIRE) -- Mark Stein, DDS, MD has been named a Super Doctor by New York Times Magazine for 2023.

Key Points: 
  • New York City, May 22, 2023 (GLOBE NEWSWIRE) -- Mark Stein, DDS, MD has been named a Super Doctor by New York Times Magazine for 2023.
  • “I am honored to be included among my peers and acknowledged as a 2023 Super Doctor,” says Dr. Stein.
  • The New York Times Super Doctors list only acknowledges doctors and physicians that have excelled above and beyond within their career field.
  • The top 5% of candidates are chosen and are then recognized for making the New York Times Super Doctors list.

SightMD Physicians named 2023 Super Doctors® and Rising Stars

Retrieved on: 
Monday, May 15, 2023
Medicine, Editorial board, Paratriathlon, DO, MD, Patient, Premature, Neuro-ophthalmology, Forehead, World Golf Village, Corneal transplantation, Face, Friends, Orbit, Research, Rockville Centre, New York, Super, Uveitis, Optic nerve, Entrepreneurship, New York Eye and Ear Infirmary, Textbook, Cataract, Abstract, Osteopathic medicine in the United States, Good Samaritan Hospital, Eye, Eyelid, Publishing, Clinical research, Engineering, Microsurgery, Family, Surgeon, CXL, Education, Cross-link, Physician, Hall, Fellow, Pleasure, Rare-earth element, Medical device, Nursing, Dentistry, Veterinary medicine, Ophthalmology, Glaucoma, PRK, Retina, LASIK

HAUPPAUGE, N.Y., May 15, 2023 /PRNewswire-PRWeb/ -- SightMD is excited to announce the growing list of providers that have been named on the 2023 "Super Doctor" and "Super Doctors Rising Stars" lists.

Key Points: 
  • SightMD is excited to announce the growing list of providers that have been named on the 2023 "Super Doctor" and "Super Doctors Rising Stars" lists.
  • HAUPPAUGE, N.Y., May 15, 2023 /PRNewswire-PRWeb/ -- SightMD is excited to announce the growing list of providers that have been named on the 2023 "Super Doctor" and "Super Doctors Rising Stars" lists.
  • said Dr. Baharestani "It is an honor to provide our patients with the highest level oculoplastic surgery services at SightMD."
  • "I am truly honored to be selected as a Super Doctors Rising Star for the 5th year in a row."

Renowned NYC Otolaryngologist Dr. Gregory Levitin Receives Castle Connolly's 2023 Top Doctor® Award

Retrieved on: 
Monday, May 8, 2023
New York Eye and Ear Infirmary, Ear, Birthmark, American Academy of Otolaryngology–Head and Neck Surgery, Glomus tumor, Castle Connolly Medical, American Academy, Hemangioma, Microcystic lymphatic malformation, Snoring, Nose, Suite, Sinusitis, MD, Patient, Physician, Cavernous venous malformation, Allergy, FACS, Columbus Circle, Medical device, Dentistry, Nightclub, Otorhinolaryngology

NEW YORK, May 8, 2023 /PRNewswire-PRWeb/ -- Dr. Gregory Levitin has been selected as a 2023 Top Doctor® by Castle Connolly. First selected in 2018, he has continued to earn this impressive award for his expertise in Otolaryngology. For patients seeking the best care, Castle Connolly publishes its list of Top Doctors at http://www.castleconnolly.com, as well as in a wide variety of partner publications, magazines and affiliate websites. After a thorough and rigorous vetting process, around 5% of the nation's licensed physicians are selected as Castle Connolly Top Doctor for their specialty.

Key Points: 
  • NEW YORK, May 8, 2023 /PRNewswire-PRWeb/ -- Dr. Gregory Levitin has been selected as a 2023 Top Doctor® by Castle Connolly.
  • First selected in 2018, he has continued to earn this impressive award for his expertise in Otolaryngology.
  • "It is always such an honor to be recognized by my peers for this award, and I consider it a significant professional accomplishment," says Dr. Gregory Levitin.
  • Dr. Gregory Levitin, MD, FACS is a board-certified otolaryngologist-head and neck surgeon and fellow of the American Academy of Otolaryngology (AAO-HNS).

Congratulations to SightMD's Exceptional Women in Medicine, Recognized as Among the Best in the Country

Retrieved on: 
Monday, April 10, 2023
Diversity, equity, and inclusion, Cornea, Meredith, Eye, Castle Connolly Medical, Woman, Research, Female, Name, Patient, Physician, Premature, DEI, New York Eye and Ear Infirmary, Exceptional Women in Publishing, Nursing, LASIK, PRK, MD, Medicine

HAUPPAUGE, N.Y., April 10, 2023 /PRNewswire-PRWeb/ -- Four of SightMD's women physicians have been recognized as among the country's top doctors. This new distinction was just rolled out by Castle Connolly Medical Ltd., a research and information company that publishes the annual guidebooks America's Top Doctors and Top Doctors: New York Metro Area. The company makes its selections based on peer nominations by 250,000 leading doctors nationwide.

Key Points: 
  • HAUPPAUGE, N.Y., April 10, 2023 /PRNewswire-PRWeb/ -- Four of SightMD's women physicians have been recognized as among the country's top doctors.
  • Congratulations to Faye Knoll, MD, Irene Magramm, MD, Michelle Liebert, MD, and Meredith Prevor-Weiss, MD, SightMD's Exceptional Women in Medicine, for gaining this well-deserved public distinction!
  • When asked about her thoughts on receiving this award Dr. Liebert said "It's an honor to be included among such exceptional women."
  • Castle Connolly's decision to shine a light on outstanding women in medicine will also encourage new generations of women to pursue careers as physicians.

Congratulations to our SightMD 2023 Castle Connolly Top Doctors

Retrieved on: 
Thursday, March 23, 2023
Medicine, Surgeon, Education, Professional, Paratriathlon, Cataract, Eye, Castle Connolly Medical, Private practice, Science, Eyelid, Patient, Premature, Physician, Optic nerve, Faculty, Hatsi, Diagnosis, New York Eye and Ear Infirmary, Transplant, FDA, Health, Neuro-ophthalmology, Medical device, Nursing, Dentistry, Retina, LASIK, Glaucoma, PRK, Ophthalmology

HAUPPAUGE, N.Y., March 23, 2023 /PRNewswire-PRWeb/ -- Earlier this year Castle Connolly announced the release of Castle Connolly Top Doctors 2023. With over 850,000 practicing doctors in the United States, Castle Connolly carefully curated the list of 63,000 plus board-certified U.S. physicians, across all 50 states and all major specialties, who comprise its network. This year marks the 30th anniversary of Castle Connolly Top Doctors. SightMD's "Top Doctors" are: Dr. Lawrence Buono, Dr. Paul Choinski, Dr. James Gordon, Dr. Allen Greenbaum, Dr. Alexander Hatsis, Dr. David Immanuel, Dr. William Kasper, Dr. Ted Karl, Dr. Neil Katz, Dr. Faye Knoll, Dr. Michelle Liebert, Dr. Irene Magramm, Dr. Jeffrey Martin, Dr. John Mauro, Dr. Richard Nattis, Dr. Seth Potash, Dr. Laurence Rubin, Dr. Norman Saffra, and Dr. Paul Sforza.

Key Points: 
  • HAUPPAUGE, N.Y., March 23, 2023 /PRNewswire-PRWeb/ -- Earlier this year Castle Connolly announced the release of Castle Connolly Top Doctors 2023.
  • With over 850,000 practicing doctors in the United States, Castle Connolly carefully curated the list of 63,000 plus board-certified U.S. physicians, across all 50 states and all major specialties, who comprise its network.
  • This year marks the 30th anniversary of Castle Connolly Top Doctors.
  • All Castle Connolly Top Doctors are nominated by their peers, and then the Castle Connolly research team evaluates important criteria to determine who makes the list, including professional qualifications, education, hospital and faculty appointments, research leadership, professional reputation, disciplinary history and interpersonal skills.

OcuSciences Announces Publication Showing Potential to Detect Retinal Diseases with High Sensitivity

Retrieved on: 
Tuesday, March 21, 2023
Biotechnology, Technology, Diabetes, Health, General Health, Optical, Health Technology, Medical Devices, Research, Software, Science, FPF, Retina, Glaucoma, New York Eye and Ear Infirmary, Institutional review board, Ranibizumab, Cell death, RVO, AMD, Visual impairment, DR, CSR, Mitochondrial disease, Retinal, Publication, Vance DeGeneres, Apoptosis, Sickle cell disease, Macular edema, Diabetic retinopathy, Patient, Frontiers Media, Disease, Medical imaging, Ophthalmology

OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced a publication in Frontiers in Ophthalmology journal.

Key Points: 
  • OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced a publication in Frontiers in Ophthalmology journal.
  • By assessing the flavoprotein fluorescence in the retina with its flagship device, the OcuMet Beacon, these findings suggest that the novel FPF measure can detect retinal diseases with a high degree of sensitivity.
  • Mitochondrial dysfunction has been documented as a precursor to apoptosis, or cell death, and is implicated in many retinal diseases and disorders.
  • The OcuMet Beacon is currently being used under Institutional Review Board at New York Eye and Ear Infirmary at Mount Sinai.

Congratulations to our SightMD 2022 Castle Connolly Top Doctors

Retrieved on: 
Friday, September 9, 2022
Cataract, Patient, Premature, Pediatric ophthalmology, Private practice, Audiology, Severe cognitive impairment, Trust, Cornea, NYU, Doctor of Philosophy, Retina, New York Eye and Ear Infirmary, Lotte Strauss, Medicine, Board, Physician, Department, Diagnosis, Science, Education, Glaucoma, Faculty, Lists of scientists, Empathy, MD, Surgeon, FDA, Hatsi, Nassau University Medical Center, Face, Eyelid, Transplant, Eye, Optic nerve, Health, Neuro-ophthalmology, Medical device, Veterinary medicine, Health insurance, Dentistry, Pharmaceutical industry, Ophthalmology, LASIK, PRK

HAUPPAUGE, N.Y., Sept. 9, 2022 /PRNewswire-PRWeb/ -- Castle Connolly announced its "2022 Top Doctors," a list that represents the top seven percent of doctors in the nation. SightMD is proud to announce that 19 of their physicians are among these standouts. SightMD's "Top Doctors" are: Dr. Alexander Hatsis, Dr. Allen Greenbaum, Dr. David Immanuel, Dr. Faye Knoll, Dr. Irene Magramm, Dr. James Gordon, Dr. Jeffrey Martin, Dr. John Mauro, Dr. Laurence Rubin, Dr. Lawrence Buono, Dr. Lawrence Zweibel, Dr. Michelle Liebert, Dr. Norman Saffra, Dr. Paul Choinski, Dr. Paul Sforza, Dr. Richard Nattis, Dr. Seth Potash, Dr. Ted Karl and Dr. William Kasper.

Key Points: 
  • HAUPPAUGE, N.Y., Sept. 9, 2022 /PRNewswire-PRWeb/ -- Castle Connolly announced its "2022 Top Doctors," a list that represents the top seven percent of doctors in the nation.
  • These outstanding doctors were nominated by their peers and thoroughly validated by Castle Connolly's research team to ensure that they deliver the highest quality patient care.
  • SightMD prides itself on having more Castle Connolly "Top Doctors" than any other practice in New York, and are thrilled to announce this year's list and recognize all of our hard working physicians.
  • With over 25 years' experience in researching, reviewing and selecting "Top Doctors," Castle Connolly is a trusted and credible source.

iHealthScreen Completed Prospective Trial of AI-Based Tool for Age-Related Macular Degeneration (AMD) Screening and Submitting the Results to FDA for 510K Clearance

Retrieved on: 
Monday, August 8, 2022
Apps, Applications, Technology, FDA, Clinical Trials, Health Technology, Telemedicine, Virtual Medicine, Biotechnology, Health, Optical, Artificial Intelligence, FDA, Interview, Diabetic retinopathy, Risk, Icahn School of Medicine at Mount Sinai, NIH, Diagnosis, AI, Glaucoma, Clinical trial, Incidence, New York Eye and Ear Infirmary, Stroke, DR, Severe cognitive impairment, AMD, IPredict, HIPAA, Ophthalmology, SBIR, Adult, Adoption, Medical device, Medicine

The initial clinical trial results show adequate accuracy for FDA clearance.

Key Points: 
  • The initial clinical trial results show adequate accuracy for FDA clearance.
  • The study was funded by NIH SBIR grants and completed with the collaboration of the New York Eye and Ear Infirmary at Mount Sinai.
  • AMD, with no early signs or symptoms, is a leading cause of adult blindness in the developed world.
  • iHealthScreen is in the final stage of submitting the results to FDA for 510K clearance.